💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Niraparib Tosylate Monohydrate

CHEMBL3989922 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
510.6 g/mol
LogP
—
Phase
4

A tosylate salt form of niraparib with the same therapeutic properties. A PARP inhibitor that blocks a DNA repair enzyme, causing cancer cells with certain genetic mutations to die.

الوزن الجزيئي

510,6000 g/mol

TPSA

137,00 Ų

المجالات العلاجية

Ovarian Cancer Breast Cancer Prostate Cancer

آلية العمل

Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1ccc(S(=O)(=O)O)cc1.NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12.O

                

                

                
                

                    
InChI

                    
InChI=1S/C19H20N4O.C7H8O3S.H2O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14;1-6-2-4-7(5-3-6)11(8,9)10;/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24);2-5H,1H3,(H,8,9,10);1H2/t14-;;/m1../s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C26H30N4O5S

                    

                    
                    

                        
HBD / HBA

                        
4 / 7

                    

                    
                    

                        
الروابط القابلة للدوران

                        
4

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
36

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
A tosylate salt form of niraparib with the same therapeutic properties. A PARP inhibitor that blocks a DNA repair enzyme, causing cancer cells with certain genetic mutations to die.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Niraparib Tosylate Monohydrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3989922.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 74763937.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.